Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) α and δ and PPAR coactivator 1α in human skeletal muscle, but not lipid regulatory genes

Skeletal Muscle Research Laboratory, School of Medical Sciences, Royal Melbourne Institute of Technology, PO Box 27, Bundoora 3083, Victoria, Australia.
Journal of Molecular Endocrinology (Impact Factor: 3.62). 10/2004; 33(2):533-44. DOI: 10.1677/jme.1.01499
Source: PubMed

ABSTRACT Fatty acids are an important ligand for peroxisome proliferator-activated receptor (PPAR) activation and transcriptional regulation of metabolic genes. To examine whether reduced plasma free fatty acid (FFA) availability affects the mRNA content of proteins involved in fuel metabolism in vivo, the skeletal muscle mRNA content of various transcription factors, transcriptional coactivators and genes encoding for lipid regulatory proteins were examined before and after 3 h of cycle exercise with (NA) and without (CON) pre-exercise ingestion of nicotinic acid (NA). NA resulted in a marked (3- to 6-fold) increase (P<0.05) in PPARalpha, PPARdelta and PPAR coactivator 1alpha (PGC1alpha) mRNA, but was without effect on nuclear respiratory factor-1 and Forkhead transcription factor, fatty acid transcolase/CD36, carnitine palmitoyl transferase 1, hormone sensitive lipase (HSL) and pyruvate dehydrogenase kinase 4. Exercise in CON was associated with increased (P<0.05) PPARalpha, PPARdelta and PGC1alpha mRNA, which was similar in magnitude to levels observed with NA at rest. Exercise was generally without effect on the mRNA content of lipid regulatory proteins in CON and did not affect the mRNA content of the measured subset of transcription factors, transcriptional co-activators and lipid regulatory proteins during NA. To determine the possible mechanisms by which NA might affect PGC1alpha expression, we measured p38 MAP kinase (MAPK) and plasma epinephrine. Phosphorylation of p38 MAPK was increased (P<0.05) by NA treatment at rest, and this correlated (r2=0.84, P<0.01) with increased PGC1alpha. Despite this close relationship, increasing p38 MAPK in human primary myotubes was without effect on PGC1alpha mRNA content. Plasma epinephrine was elevated (P<0.05) by NA at rest (CON: 0.27+/-0.06, NA: 0.72+/-0.11 nM) and throughout exercise. Incubating human primary myotubes with epinephrine increased PGC1alpha independently of changes in p38 MAPK phosphorylation. Hence, despite the fact that NA ingestion decreased FFA availability, it promoted the induction of PPARalpha/delta and PGC1alpha gene expression to a similar degree as prolonged exercise. We suggest that the increase in PGC1alpha may be due to the elevated plasma epinephrine levels. Despite these changes in transcription factors/coactivators, the mRNA content of lipid regulatory proteins was generally unaffected by plasma FFA availability.

Download full-text


Available from: Mark A Febbraio, Feb 22, 2014
  • Source
    • "In other words, a greater PGC-1 protein content may boost the 'transcriptional sensitivity' of the cell to further exercise challenges. These potential benefits of increased transcriptional protein expression may also apply to other transcription factors, especially considering that both acute and chronic exercise increases the expression of many of the NRFs (Short et al. 2003; Cartoni et al. 2005), PPARs (Horowitz et al. 2000; Russell et al. 2003; Watt et al. 2004; Russell et al. 2005) and Tfam (Bengtsson et al. 2001; Pilegaard et al. 2003; Short et al. 2003; Garcia-Roves et al. 2006; Norrbom et al. 2010) in human skeletal muscle. The improved oxidative capacity of skeletal muscle following training may also be due to alterations in mitochondrial morphology in addition to a greater mitochondrial content. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Exercise training induces mitochondrial biogenesis, but the time course of molecular sequelae that accompany repetitive training stimuli remains to be determined in human skeletal muscle. Therefore, throughout a seven-session, high-intensity interval training period that increased (12%), we examined the time course of responses of (a) mitochondrial biogenesis and fusion and fission proteins, and (b) selected transcriptional and mitochondrial mRNAs and proteins in human muscle. Muscle biopsies were obtained 4 and 24 h after the 1st, 3rd, 5th and 7th training session. PGC-1α mRNA was increased >10-fold 4 h after the 1st session and returned to control within 24 h. This 'saw-tooth' pattern continued until the 7th bout, with smaller increases after each bout. In contrast, PGC-1α protein was increased 24 h after the 1st bout (23%) and plateaued at +30-40% between the 3rd and 7th bout. Increases in PGC-1β mRNA and protein were more delayed and smaller, and did not persist. Distinct patterns of increases were observed in peroxisome proliferator-activated receptor (PPAR) α and γ protein (1 session), PPAR β/δ mRNA and protein (5 sessions) and nuclear respiratory factor-2 protein (3 sessions) while no changes occurred in mitochondrial transcription factor A protein. Citrate synthase (CS) and β-HAD mRNA were rapidly increased (1 session), followed 2 sessions later (session 3) by increases in CS and β-HAD activities, and mitochondrial DNA. Changes in COX-IV mRNA (session 3) and protein (session 5) were more delayed. Training also increased mitochondrial fission proteins (fission protein-1, >2-fold; dynamin-related protein-1, 47%) and the fusion protein mitofusin-1 (35%) but not mitofusin-2. This study has provided the following novel information: (a) the training-induced increases in transcriptional and mitochondrial proteins appear to result from the cumulative effects of transient bursts in their mRNAs, (b) training-induced mitochondrial biogenesis appears to involve re-modelling in addition to increased mitochondrial content, and (c) the 'transcriptional capacity' of human muscle is extremely sensitive, being activated by one training bout.
    The Journal of Physiology 10/2010; 588(Pt 23):4795-810. DOI:10.1113/jphysiol.2010.199448 · 4.54 Impact Factor
  • Source
    • "Signalling downstream from the niacin receptor has been shown to involve induction and activation of PPARg expression in both adipocytes and macrophages, while activation of HM74A has been shown to induce both expression and transcriptional activation of PPARg in human macrophages (Zhao et al., 2008). Interestingly, niacin has also been shown to up-regulate expression of PPARa and d in skeletal muscle, an effect similar to that observed with chronic low-intensity exercise (Watt et al., 2004), although paradoxically, niacin appears to attenuate the beneficial effects of exercise in terms of lowering plasma TGs (Plaisance et al., 2008). Niacin has also been shown to up-regulate both transcription and nuclear translocation of PPARg in both liver and monocytoid cells, and to increase the transcription of two known PPARg targets; CD36, a scavenger receptor known to be involved in the uptake of modified lipids by macrophages, and ABCA1, one of the major reverse cholesterol transporters in macrophages , responsible for the ApoA1-mediated transfer of intracellular cholesterol to HDL particles (Nicholson, 2004; Rubic et al., 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dyslipidaemias, particularly those characterized by the 'atherogenic profile' of high low-density lipoprotein-cholesterol and triglycerides and low high-density lipoprotein-cholesterol, are the major modifiable risk factor for atherosclerosis. The search for drugs to favourably alter such lipid profiles, reducing the associated morbidity and mortality, remains a major research focus. Niacin (nicotinic acid) is the most effective agent available for increasing high-density lipoprotein-cholesterol, but its use is associated with side effects that negatively affect patient compliance: these appear to arise largely as a result of production of prostaglandin D(2) and its subsequent activation of the DP(1) receptor. Desire to reduce the side effects (and improve pharmacokinetic parameters) has led to the development of a number of agonists that have differing effects, both in terms of clinical potency and the severity of adverse effects. The recent discovery of the niacin G-protein-coupled receptor HM74A (GPR109A) has clarified the distinction between the mechanism whereby niacin exerts its therapeutic effects and the mechanisms responsible for the generation of side effects. This has allowed the development of new drugs that show great potential for the treatment of dyslipidaemia. However, recent advances in understanding of the contribution of prostaglandin metabolism to vascular wall health suggest that some of the beneficial effects of niacin may well result from activation of the same pathways responsible for the adverse reactions. The purpose of this review is to emphasize that the search for agonists that show higher tolerability must take into account all aspects of signalling through this receptor.
    British Journal of Pharmacology 08/2009; 158(2):429-41. DOI:10.1111/j.1476-5381.2009.00349.x · 4.99 Impact Factor
  • Source
    • "A palmitate-induced (0.75 mmolÁL –1 ) reduction in PGC-1a has been observed in C2C12 muscle cells, and appears to involve MAPK-extracellular signal-related kinase 1/2 and nuclear factor-kb activation (Coll et al. 2006). In humans, suppression of plasmafree fatty acid (Watt et al. 2004) increased PGC-1a mRNA (Watt et al. 2004), while conversely, a high-fat diet (Sparks et al. 2005) and lipid infusion (increased circulating fatty acids 3.6-fold (Richardson et al. 2005)) reduced muscle PGC-1a protein (–40%) (Sparks et al. 2005) and mRNA (30%–90%) (Richardson et al. 2005; Sparks et al. 2005). Thus, it appears that increasing circulating fatty acids alters PGC-1a in a reciprocal manner. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The peroxisome proliferator-activated receptor gamma (PPARgamma) coactivator 1alpha (PGC-1alpha), a nuclear encoded transcriptional coactivator, increases the expression of many genes in skeletal muscle, including those involved with fatty acid oxidation and oxidative phosphorylation. Exercise increases the expression of PGC-1alpha, and the exercise-induced upregulation of many genes is attributable, in part, to the preceding activation and upregulation of PGC-1alpha. Indeed, PGC-1alpha overexpression, like exercise training, increases exercise performance. PGC-1alpha reductions in humans have been observed in type 2 diabetes, while, in cell lines, PGC-1alpha mimics the exercise-induced improvement in insulin sensitivity. However, unexpectedly, in mammalian muscle, PGC-1alpha overexpression contributed to the development of diet-induced insulin resistance. This may have been related to the massive overexpression of PGC-1alpha, which induced the upregulation of the fatty acid transporter FAT/CD36 and led to an increase in intramuscular lipids, which interfere with insulin signalling. In contrast, when PGC-1alpha was overexpressed modestly, within physiological limits, mitochondrial fatty acid oxidation was increased, GLUT4 expression was upregulated, and insulin-stimulated glucose transport was increased. More recently, similar PGC-1alpha-induced improvements in the insulin-resistant skeletal muscle of obese Zucker rats have been observed. These studies suggest that massive PGC-1alpha overexpression, but not physiologic PGC-1alpha overexpression, induces deleterious metabolic effects, and that exercise-induced improvements in insulin sensitivity are induced, in part, by the exercise-induced upregulation of PGC-1alpha.
    Applied Physiology Nutrition and Metabolism 07/2009; 34(3):307-14. DOI:10.1139/H09-008 · 2.23 Impact Factor
Show more